Coeptis Therapeutics Inc.

Operating margin

−18977.4%

Net margin

−17932.4%

Return on equity

−572.2%

Return on assets

−198.8%

Return on capital (ROCE)

−355.8%

Liabilities / assets

65.3%

Debt / equity

1.88×

Book value / share

$0.06

Revenue growth (YoY)

143.8%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

-27.42distress

Accruals / assets

−132.4%clean

Piotroski F-Score

5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Shareholder voteOct 28, 2022
• Regulation FD disclosure · Other material eventSep 21, 2022
• Entered a material agreement · Regulation FD disclosureSep 7, 2022
• Terminated a material agreementAug 22, 2022
• Regulation FD disclosure · Other material eventJul 6, 2022
• Other material eventMay 17, 2022
• Entered a material agreement · Regulation FD disclosureApr 19, 2022
• Entered a material agreementApr 12, 2022

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.